A Phase I/II Study of LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma
Status: Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 12 Aug 2019
Price : $35 *
At a glance
- Drugs IMC CS4 (Primary) ; Cobimetinib; Vemurafenib
- Indications Malignant melanoma
- Focus Therapeutic Use
- 06 Aug 2019 Planned End Date changed from 30 Oct 2023 to 31 Dec 2020.
- 06 Aug 2019 Status changed from recruiting to active, no longer recruiting.
- 31 Aug 2018 Biomarkers information updated